lobbying_activities: 2020118

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2020118	cfd419cc-0643-4fc4-b6c4-98d1a80c1f9b	Q3	COMMUNITY ONCOLOGY ALLIANCE	400874561	COMMUNITY ONCOLOGY ALLIANCE	2017	third_quarter	MMM	Application of the sequester cut to Medicare Part B drug reimbursement (no bill). Fixing the 340B drug discount program (no bill). Fixing Medicare Part B drug reimbursement by eliminating the manufacturer-to-wholesaler prompt pay discount from the calculation of average sales price, the basis of Part B drug reimbursement (H.R. 1920, S. 1304). Misc. issues dealing with pharmacy benefit managers and patient and pharmacy abuses (includes bills H.R 1316 - Prescription Drug Price Transparency Act and H.R.1038 - Improving Transparency and Accuracy in Medicare Part D Spending Act. Medicare oncology payment reform (includes bills S. 463 - Cancer Care Payment Reform Act of 2017 and H.R. 1834 - Cancer Care Payment Reform Act of 2017. Oncology Care Model (CMS/CMMI; no bill).	Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE		111500	0	0	2017-10-05T18:15:55.310000-04:00